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Summary
Background—Worldwide implementation of risk-based cardiovascular disease (CVD) 
prevention requires risk prediction tools that are contemporarily recalibrated for the target country 
and can be used where laboratory measurements are unavailable. We present two cardiovascular 
risk scores, with and without laboratory-based measurements, and the corresponding risk charts 
for 182 countries to predict 10-year risk of fatal and non-fatal CVD in adults aged 40–74 years.
Methods—Based on our previous laboratory-based prediction model (Globorisk), we used data 
from eight prospective studies to estimate coefficients of the risk equations using proportional 
hazard regressions. The laboratory-based risk score included age, sex, smoking, blood pressure, 
diabetes, and total cholesterol; in the non-laboratory (office-based) risk score, we replaced 
diabetes and total cholesterol with BMI. We recalibrated risk scores for each sex and age group in 
each country using country-specific mean risk factor levels and CVD rates. We used recalibrated 
risk scores and data from national surveys (using data from adults aged 40–64 years) to estimate 
the proportion of the population at different levels of CVD risk for ten countries from different 
world regions as examples of the information the risk scores provide; we applied a risk threshold 
for high risk of at least 10% for high-income countries (HICs) and at least 20% for low-income 
Ueda et al. Page 2
Lancet Diabetes Endocrinol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and middle-income countries (LMICs) on the basis of national and international guidelines for 
CVD prevention. We estimated the proportion of men and women who were similarly categorised 
as high risk or low risk by the two risk scores.
Findings—Predicted risks for the same risk factor profile were generally lower in HICs than in 
LMICs, with the highest risks in countries in central and southeast Asia and eastern Europe, 
including China and Russia. In HICs, the proportion of people aged 40–64 years at high risk of 
CVD ranged from 1% for South Korean women to 42% for Czech men (using a ≥10% risk 
threshold), and in low-income countries ranged from 2% in Uganda (men and women) to 13% in 
Iranian men (using a ≥20% risk threshold). More than 80% of adults were similarly classified as 
low or high risk by the laboratory-based and office-based risk scores. However, the office-based 
model substantially underestimated the risk among patients with diabetes.
Interpretation—Our risk charts provide risk assessment tools that are recalibrated for each 
country and make the estimation of CVD risk possible without using laboratory-based 
measurements.
Introduction
Cardiovascular diseases (CVDs) are the leading cause of death and disability worldwide, and 
over three-quarters of CVD deaths occur in low-income and middle-income countries 
(LMICs).1 An effective strategy for CVD prevention is to provide lifestyle counselling to 
people at high risk of an event, with or without prescription of medications to lower blood 
pressure and serum cholesterol. As part of the global response to non-communicable 
diseases (NCDs), countries have agreed to a 50% target for coverage of counselling and 
treatment for people who are at high risk of CVDs, including ischaemic heart disease (IHD) 
and stroke.1,2
The risk-based approach to CVD prevention requires identification of high-risk people (eg, 
those with ≥30% risk of having a cardiovascular event in 10 years),2,3 which is done with 
risk prediction equations, often presented as risk charts. A risk prediction equation estimates 
a person’s risk of CVD during a specific time period using measures of their CVD risk 
factors and a set of weights, usually log hazard ratios, that quantify the proportional effect of 
each risk factor on CVD risk. Risk equations developed in one population cannot be applied 
to other populations, or even used in the same population years after they were developed, 
because mean CVD risk and CVD risk factor levels vary across populations and over 
time.4,5 This challenge can be dealt with by recalibrating the risk prediction equation; that is, 
resetting the mean risk factor levels and disease risk to current levels for the target 
population.6–8 However, such recalibration is rarely done because most countries do not 
have the information needed, and current risk equations are difficult to recalibrate.9 A 
previous set of risk charts published by WHO only provided predicted CVD risk for regions 
and not individual countries.3 The absence of reliable contemporary risk charts for all 
countries presents a major obstacle for worldwide implementation of risk-based prevention. 
A second obstacle is that most risk prediction equations require measurements of blood 
glucose and lipids, which makes implementation of risk assessment too costly or impractical 
in resource-poor settings.
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We previously presented a novel approach for risk prediction in global populations 
(Globorisk)9 and applied the methods to predict 10-year risk of fatal CVD in 11 countries. 
Here, we used the same methods to estimate the 10-year risk of fatal and non-fatal CVD and 
to recalibrate the models using updated data for 182 countries. We also generated 
corresponding risk charts using an alternative model that relies only on risk factors that do 
not require blood tests. We then assessed a two-stage strategy using a combination of the 
two risk scores to identify high-risk individuals and limit the number of patients who need 
laboratory tests.
Methods
Statistical analysis and coefficients of risk prediction equations
As described in detail elsewhere,9 we generated a laboratory-based risk prediction equation 
using data from eight cohort studies in the USA and a Cox proportional hazards model 
stratified by sex and cohort that used age as the timescale.10 Risk factors used in the 
laboratory-based mode included smoking, blood pressure, diabetes, and total cholesterol. We 
allowed the coefficients of risk factors to vary with age because CVD hazard ratios often 
decrease by age.11 We also included interaction terms between sex and diabetes and sex and 
smoking, because diabetes and smoking are stronger predictors of CVD in women than in 
men.12,13 Fatal and non-fatal CVD comprised deaths from IHD, sudden cardiac death or 
stroke (International Classification of Diseases [ICD] 10 codes I20–I25 and I60–I69) and 
nonfatal myocardial infarction (ICD-10 codes I21–I22) and stroke (ICD-10 codes I60–I69).
We then modified this model to generate an office-based model, in which we replaced total 
cholesterol and diabetes with BMI because there is a strong association between BMI and 
both diabetes and cholesterol because of the direct effect of excess weight on these 
physiological traits.14 Additionally, common factors such as poor diet and physical inactivity 
contribute to increased bodyweight, blood glucose, and serum cholesterol. As supported by 
previous research,15 an interaction term between sex and BMI did not improve risk 
prediction, and was therefore not included.
We did an internal validation of the models by assessing the ability of the risk score to assign 
a higher risk to individuals with a shorter time to event (discrimination) using Harrell’s C 
statistics and by comparing the predicted and observed 10-year risk by deciles of risk 
(calibration; appendix pp 2, 3). We compared the proportion of participants who went on to 
develop CVD during follow-up who were categorised as high risk by the two risk scores 
(sensitivity), as well as the proportion of participants who were free of CVD at the end of 
follow-up who were categorised as low risk (specificity) using 10%, 20%, and 30% 10-year 
CVD risk as thresholds for high risk versus low risk. Finally, we did an external validation of 
the model in three cohorts that had not been used to estimate the risk prediction equation 
(Tehran Lipid and Glucose Study, Scottish Heart Health Extended Cohort, and The 
Australian Diabetes, Obesity and Lifestyle Study; appendix p 7).
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Recalibration of the risk scores
The recalibration procedure is described in detail elsewhere.9 Briefly, we replaced mean risk 
factor levels and CVD event rates in each 5-year age group and by sex with the best current 
estimates of these quantities for the target country. Age-specific and sex-specific estimates 
of mean risk factor levels were taken from global analyses of health examination 
surveys.16–20 We estimated fatal and non-fatal IHD and stroke rates for each country and age 
and sex group by dividing the WHO IHD and stroke death rates21 by the case fatality rates.
To obtain case fatality estimates, we first considered that case fatality varies by region and is 
higher in LMICs than high-income countries (HICs).22,23 We thus used previously published 
estimates of 28-day case fatality rates by region for IHD22 and by country income level for 
stroke,23 and converted these to 1-year case fatality rates using methods explained in the 
appendix (appendix pp 3–6, 8). Case fatality also increases with age. To convert the all-age 
case fatality rates to age-specific rates, we used the age pattern of 1-year case fatality rates 
reported in nationwide Swedish registries (appendix pp 3–6, 13, 14).
The total (fatal and non-fatal) CVD rate in each age and sex country group was calculated 
as:
This formula allows for the potential overlap between non-fatal IHD and stroke (eg, a stroke 
event in the same person after a non-fatal IHD), which tends to happen in people in whom 
IHD and stroke rates are higher (eg, elderly people), therefore reducing potential bias when 
simply adding non-fatal IHD and stroke rates. In the eight US cohorts, we estimated that 
simply adding non-fatal IHD and stroke rates would overestimate the observed CVD rates 
by three to 31 per 1000 person-years, whereas the aforementioned method reduces the bias 
by up to 63%. Once fatal and non-fatal CVD rates were estimated, they were projected for 9 
years (ie, 2016–24) using trends from 2000–15 and a log-linear model.
We used the recalibrated risk scores to generate risk charts for 182 of the 193 WHO member 
states for which we had data on CVD death. In the main paper, we present risk charts for the 
most populous countries in each region as examples. We limited prediction to those aged 
40–74 years because this range is commonly used for assessment of primary prevention of 
CVD, and CVD death rates in those aged 85 years and older are less reliable.
Application in national surveys
We used the recalibrated laboratory-based risk equation and individual-level data from 
nationally representative surveys to estimate the proportion of the population at different 
levels of CVD risk in ten countries with recent (2007 or later) surveys (appendix p 9). Since 
surveys in Cambodia, Czech Republic, Iran, and Uganda only included people aged 40–64 
years, we used this age range to compare the proportion of individuals who are at high risk 
across the ten countries. For each country, we compared the mean 10-year risk of fatal CVD 
from the previously published Globorisk model,9 with the 10-year risk of fatal and non-fatal 
CVD predicted by the updated laboratory-based and office-based risk scores. We also used 
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scatter plots to compare predicted risks for each individual and estimated the proportion of 
men and women who were categorised as low risk or high risk by the two risk scores. We 
considered three different thresholds to define high risk: 10% for HICs, 20% in LMICs on 
the basis of recent guidelines,3,24–26 and 30% in LMICs as the threshold used in the global 
NCD target.2
We also assessed a two-stage strategy that could be used to identify high-risk individuals in 
resource-poor settings. In this strategy, patients would be first assessed using the office-
based risk score and those with a predicted risk that was just below the threshold for high 
risk (ie, potential false negatives) would be referred for further laboratory testing. We then 
estimated the proportion of patients at high risk who were identified by the office-based risk 
score and established the range of office-based risk levels at which further laboratory tests 
would be needed to identify 95% of those at high laboratory-based risk.
Analyses were done with Stata 12.0. The study protocol was approved by the institutional 
review board at the Harvard T.H. Chan School of Public Health (Boston, MA, USA).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. PU, KH, and GD had full access to all the data in the 
study and GD had final responsibility for the decision to submit for publication.
Results
We included 50 129 participants from eight cohorts in the estimation of the proportional 
hazards models; characteristics of the population were reported previously.9 Table 1 shows 
the coefficients for the risk scores. Both risk scores performed well in internal and external 
validation (appendix p 11). In the internal validation, the C statistic was 0·71 (95% CI 0·70–
0·72) for the laboratory-based model and 0·69 (0·68–0·70) for the office-based model. In the 
external validation, the C statistic ranged from 0·73 to 0·78 for the laboratory-based model 
and from 0·70 to 0·77 for the office-based model (appendix p 12). Both models predicted 
risks that were close to those observed in internal and external validation (appendix pp 11, 
12).
The mean 10-year risk of fatal and non-fatal CVD was similar between the two risk scores 
and was higher than the risk of fatal CVD (table 2). In the pooled eight US cohorts and using 
10% as the risk threshold, the laboratory-based risk score categorised 1956 (65·1% [95% CI 
64·2–65·9]) and the office-based risk score categorised 1881 (62·6% [61·7–63·5]) of the 
3005 participants who later had a CVD event as high risk (appendix p 10).
At any age and risk factor level, the 10-year risk of CVD varied substantially across 
countries for both models. Overall, predicted risks in the country risk charts were lower in 
HICs than in LMICs, with the highest risks estimated for the same risk profile in southeast 
and central Asia and eastern Europe (appendix pp 23–388). Figure 1 shows risk charts based 
on the laboratory-based model for ten highly populous countries. The predicted 10-year 
CVD risk for a non-smoking 65-year-old man with diabetes, a systolic blood pressure of 160 
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mm Hg, and a total cholesterol of 6 mmol/L spanned from 21% in Japan and the USA to 
53% in China, and the predicted risks for the same profile for a smoker ranged from 26% in 
Japan to 62% in China (figure 1). The complete set of risk charts is presented in the 
appendix (pp 23–388) and a risk calculator is available from Globorisk.
Distribution of 10-year risk of CVD using the laboratory-based model varied substantially 
across countries (figure 2). The share of the population with an at least 10% CVD risk in the 
four HICs ranged from 7% for men and 1% for women in South Korea to 42% for men and 
15% for women in the Czech Republic. In the four middle-income countries, the percentage 
of population with at least 20% CVD risk ranged from 3% for men and 2% for women in 
Jamaica to 13% for men and 11% for women in Iran. In the two low-income countries, the 
percentage of people who had at least 20% risk was less than 2% in Uganda and 9% in 
Cambodia in both men and women.
When using a 10% risk threshold for high risk in HICs, the two risk scores assigned the 
same risk status to 85–93% of men and 89–95% of women in each country (figure 3). The 
corresponding percentages using a 20% threshold for middle-income countries were 90–
96% in men and 89–95% in women; and for low-income countries they were 94–95% to 
99% for both men and women (figure 3; appendix pp 389–95). The largest differences 
between the risks estimated using the two models occurred among people with diabetes, in 
whom the office-based model underestimated risk by 23–75% at various ages across the ten 
countries (figure 4, appendix pp 389–95). Accordingly, the proportion of the population 
correctly categorised as low risk or high risk using the office-based model was lower in 
countries with a high diabetes prevalence (eg, Mexico and Iran; figure 3).
Figure 5 shows the potential of a two-stage strategy to identify individuals with high CVD 
risk in ten countries. In the four HICs shown, the percentage of individuals at high risk 
(≥10% laboratory-based CVD risk) who were identified correctly by the office-based risk 
score (ie, sensitivity) was 66–82% among men and 36–71% among women (figure 5). In 
these countries, between 14% and 61% of the population who had a borderline risk would 
need further laboratory tests to identify 95% of those at high risk. In LMICs, the proportion 
of high-risk (≥20% laboratory-based CVD risk) individuals who were identified correctly by 
the office-based risk score varied from 33% to 83%, and the percentage of the population 
that would need laboratory tests to correctly identify 95% of those at high risk ranged from 
11% to 50%.
Discussion
We developed CVD risk charts to predict fatal and non-fatal CVD, with and without 
laboratory-based measurements, for 182 countries. These risk charts will facilitate 
worldwide implementation of risk-based prevention by providing health-care professionals 
with risk assessment tools that are recalibrated for each country and can be used in settings 
without access to laboratory-based measurements. The predicted risk for the same risk factor 
profile tended to be lower in HICs than in LMICs, a pattern that was also reported in the 
Prospective Urban and Rural Epidemiological study.27 When risk scores were applied to 
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data from national health surveys, prevalence of high CVD risk varied substantially by 
country and sex and was generally lower in HICs than in LMICs.
Our risk scores and risk charts will be particularly useful in LMICs because most of these 
countries do not have locally developed risk scores. Additionally, the office-based risk score 
allows for risk prediction in environments where there is little or no access to a laboratory, 
such as during home care visits. Similar to findings from previous research,28 more than 
80% of adults were similarly classified as low risk or high risk by laboratory-based and 
office-based risk scores. However, we noted that the office-based risk score substantially 
under estimated the risk among people with diabetes.
In several LMICs (eg, Uganda, China, and Jamaica), a two-stage strategy using the 20% risk 
threshold for high risk seemed efficient because a relatively small proportion (11–30%) of 
individuals with borderline office-based risk would need further laboratory tests to detect 
95% of high-risk individuals. By contrast, about half of women in Cambodia and men in 
Mexico would need further laboratory tests. Further development of office-based risk 
scoring strategies should use country-specific risk thresholds and balance the benefits of 
reducing costs with the possibility of missing truly high-risk individuals. Where a difference 
was noted between the laboratory-based and office-based scores, it was mostly among 
patients with diabetes, highlighting the importance of including a diagnosis of diabetes in 
the risk score if laboratory measurements are available. Also, inclusion of diabetes in the 
laboratory-based risk score would further motivate screening for diabetes, which remains 
largely undiagnosed in LMICs.29 Therefore, integrating diabetes diagnosis into CVD risk 
stratification programmes will improve early detection and management of diabetes and 
risk-based CVD prevention.
Most existing risk scores have been developed for specific populations.30,31 WHO developed 
regional risk charts in 2007,3 but individual coefficients of the risk score were not derived 
from the same regression model or even from a consistent set of epidemiological studies. 
Moreover, risk charts were only presented for regions and not for individual countries, 
although CVD risk differs between countries in the same region.21 The only other country-
specific risk score, the Systematic Coronary Risk Evaluation (SCORE), provides risk charts 
for European countries.32 However, the charts only predict risk of fatal CVD, which 
disfavours younger individuals who have a proportionally higher risk of non-fatal CVD. 
Moreover, SCORE risk charts do not include diabetes, which is an important predictor of 
CVD.
In addition to providing a unified risk score and risk charts that can be used for all countries, 
our risk charts can be easily updated as new national data on mean risk factor levels and 
CVD rates become available. Our risk scores also include interactions between age and risk 
factors. The age interactions improve risk prediction, and, because the interactions are 
negative, they help to highlight the need for intervention in younger individuals with 
increased risk factor levels whose lifetime risk of CVD is high.33 In fact, as evident in the 
risk charts, the predicted risk for individuals with high levels of several risk factors does not 
increase substantially with age. Other strengths of the study are the use of high-quality 
prospective cohorts to estimate risk score coefficients, and application of the risk score to 
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individual-level, national data from countries in different world regions to estimate 
prevalence of high CVD risk. The use of national in-country data is distinct from the 
summary statistics used in the 2007 WHO report,3 which do not take into account 
associations between different CVD risk factors in each country.
Our study has some limitations. First, because national CVD incidence data are not available 
for most countries, we estimated fatal and non-fatal CVD rates using national IHD and 
stroke death rates from WHO,21 and estimates of case fatality rates by age, sex, and 
region.22,23 Our estimated CVD rates were close to those reported in nationwide studies and 
health registries in several HICs. However, this estimation had a few limitations: (1) WHO 
death rates in countries with incomplete vital registration are estimated using partial 
information and demographic and epidemiological methods;34 (2) we used the age pattern of 
case fatality from Sweden, where high-quality data were available from more than 1 million 
events in registries, because age-specific case fatality rates were not available from other 
countries; and (3) the CVD rates that we used for recalibration overestimated the true rates 
because we ignored the positive association between non-fatal IHD and stroke events 
because of their shared risk factors. Empirical data to quantify this association for all 
countries are not available. The scarcity of data on CVD rates underscores the need for 
monitoring. Second, although the coefficients of the risk scores were derived from eight 
high-quality cohorts of diverse ethnic origins, all cohorts were from the USA and Puerto 
Rico. Evidence from cohort pooling shows that the proportional effects of risk factors are 
similar in so-called western (North America, western Europe, Australia, and New Zealand) 
and Asian populations, and over time in the same populations.11,35 Future research should 
include pooling studies across different regions. Third, in our application of the risk score in 
country surveys, we did not account for patients with a previous CVD event who are at high 
risk of a future event and should receive treatment. Fourth, we used 10%, 20%, and 30% as 
thresholds to define high risk on the basis of national and international guidelines for CVD 
prevention.3,24–26 However, the threshold above which a patient is judged to be high risk and 
thus eligible for counselling and treatment depends on the priorities set for disease control in 
each country. The threshold also changes the sensitivity and specificity of the risk score, 
which also vary across countries. Finally, we presented 10-year CVD risk because this is the 
most commonly used timeframe in risk scores and risk charts. However, 10-year risks 
underestimate lifetime risk and might therefore lead to under-treatment, especially in 
younger individuals.
Risk-based prevention of CVD is a major strategy proposed by national and international 
guidelines.3,24,25 The risk charts presented here can be used to predict 10-year risk of fatal 
and non-fatal CVD in 182 countries worldwide, removing a major obstacle in applying risk-
based prevention strategies both for individuals and populations. Further research is needed 
to identify the most cost-effective interventions for high-risk individuals. Trials are ongoing 
to establish whether the efficacy of multidrug treatment and lifestyle advice in LMICs is 
similar to those in high-income countries. Research is also ongoing into whether non-
physician clinicians, aided by new information technologies such as risk charts, can 
successfully identify and manage high-risk individuals, especially if regular contact leads to 
better adherence.
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Research in context
Evidence before this study
We searched PubMed (last search done Oct 1, 2016) for articles related to cardiovascular 
disease (CVD) risk prediction in global populations using the following key terms: 
“cardiovascular disease”, “risk prediction”, “risk score”, “risk equation”, “developing 
countries”, “low-income and middle-income countries”, and “global”. No language 
restrictions were set. We reviewed the 209 articles retrieved from this search to find those 
that included risk prediction equations that could be applied to more than one country. 
Only three risk prediction equations qualified for our review and each had major 
limitations. WHO presented regional risk charts in 2007; however, the individual 
coefficients of the risk score were not derived from the same regression model or even 
from the same set of epidemiological studies, and cardiovascular risk patterns might 
differ between countries in the same subregion. The Systematic Coronary Risk 
Evaluation (SCORE) provided separate risk charts for European countries, but the risk 
charts only predicted risk of fatal CVD and did not include diabetes, which is an 
important predictor of CVD. Finally, the INTERHEART Modifiable Risk score was 
developed from a multi-country case-control study, unlike other models that are based on 
prospective cohorts, and did not include stroke as an outcome.
Added value of this study
We provided risk scores, with and without laboratory-based measurements, for prediction 
of 10-year risk of fatal and non-fatal CVD and recalibrated the risk scores to produce risk 
charts for 182 countries. The two risk scores are designed in a way that allows and 
necessitates updating as new data on mean risk factor levels and CVD rates become 
available.
Implications of all the available evidence
Our risk charts facilitate worldwide implementation of risk-based prevention by 
providing health-care professionals with risk assessment tools that are recalibrated for 
each country and can be used in settings without access to laboratory-based 
measurements.
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Figure 1. Laboratory-based country risk charts for 10-year risk of fatal and non-fatal 
cardiovascular disease for ten highly populous countries
To establish a person’s risk, identify the column that represents the person’s sex, smoking, 
and diabetes status. Then identify the closest cell that represents the person’s age, total 
cholesterol, and systolic blood pressure.
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Figure 2. Distributions of 10-year risk of fatal and non-fatal cardiovascular disease by country 
and sex in people aged 40–64 years using the laboratory-based model
Countries are ranked by mean risk in the population for each sex. HIC=high-income country. 
LIC=low-income country. MIC=middle-income country.
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Figure 3. Percentage of the population in national health surveys categorised as high or low risk 
by the office-based and laboratory-based risk scores at three different threshold levels used to 
define high risk
Countries are ordered by increasing diabetes prevalence. The surveys for Cambodia, Czech 
Republic, Iran, and Uganda include people aged 40–64 years, and the remaining surveys 
include people aged 40–74 years.
HIC=high-income country. LIC=low-income country. MIC=middle-income country.
Ueda et al. Page 25
Lancet Diabetes Endocrinol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Scatter plot of individual-level risk of fatal and non-fatal cardiovascular disease 
predicted using the office-based versus laboratory-based model in people aged 40–74 years in the 
Chinese Health and Nutrition Survey 2009 by diabetes status
Red lines show 20% risk. China is shown as an example; all other scatter plots are provided 
in the appendix pp 389–95. CVD=cardiovascular disease.
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Figure 5. Assessment of a two-stage strategy to identify individuals at high risk of fatal and non-
fatal cardiovascular disease in ten countries with a recent national health survey
Countries are ordered by income (World Bank groups) and increasing diabetes prevalence. 
The surveys for Cambodia, Czech Republic, Iran, and Uganda include people aged 40–64 
years, and the remaining surveys include people aged 40–74 years. CVD=cardiovascular 
disease. HIC=high-income country. LIC=low-income country. MIC=middle-income country.
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Table 1
Coefficients from the Cox proportional hazard models for laboratory-based and office-based risk scores
Coefficients (log HR [95% CI]) HR (95% CI)*
Main effect Age interaction term†
Laboratory based‡
Systolic blood pressure
(per 10 mm Hg)
0·3070 (0·2298 to 0·3842) −0·0022 (−0·0034 to −0·0011) 1·18 (1·16 to 1·19)
Total cholesterol
(per 1 mmol/L)
0·6149 (0·4631 to 0·7667) −0·0069 (−0·0092 to −0·0045) 1·19 (1·16 to 1·22)
Diabetes 1·4753 (0·9921 to 1·9585) −0·0132 (−0·0205 to −0·0059) 1·88 (1·71 to 2·06)
Female with diabetes 0·4050 (0·2523 to 0·5578) ·· 1·50 (1·29 to 1·75)
Smoker 1·8467 (1·4192 to 2·2741) −0·0221 (−0·0289 to −0·0152) 1·55 (1·44 to 1·66)
Female smoker 0·3254 (0·1893 to 0·4614) ·· 1·38 (1·21 to 1·59)
Office based
Systolic blood pressure
(per 10 mm Hg)
0·3037 (0·2264 to 0·3811) −0·0021 (−0·0033 to −0·0009) 1·18 (1·17 to 1·20)
BMI (per 5 kg/m2) 0·3245 (0·1288 to 0·5201) −0·0030 (−0·0060 to 0·0000) 1·14 (1·11 to 1·17)
Smoker 1·7951 (1·3651 to 2·2251) −0·0215 (−0·0284 to −0·0146) 1·52 (1·42 to 1·64)
Female smoker 0·3528 (0·2170 to 0·4886) ·· 1·42 (1·24 to 1·63)
CVD=cardiovascular disease. HR=hazard ratio.
*
HRs for systolic blood pressure, total cholesterol, diabetes, smoking, and BMI are shown at median age of CVD event, which is 64 years in the 
included cohorts; HRs for smoking and diabetes are for men, and their interaction with sex shows the additional risk among women.
†
Included because the HRs for effects on CVD decrease with age;15–17 therefore, the HR at any age depends on the main effect and interaction 
terms.
‡
Previously published data9 reported here for comparison between laboratory-based and office-based risk scores.
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